In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Corcept Therapeutics (CORT – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $25.47.
Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Revance Therapeutics, and Corcept Therapeutics. According to TipRanks, Amsellem has an average return of -6.3% and a 38.20% success rate on recommended stocks.
Currently, the analyst consensus on Corcept Therapeutics is a Strong Buy with an average price target of $36.83.
See the top stocks recommended by analysts >>
Based on Corcept Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $117.72 million and a net profit of $27.53 million. In comparison, last year the company earned a revenue of $103.39 million and had a net profit of $27.41 million
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CORT in relation to earlier this year. Most recently, in September 2023, Lyon Joseph Douglas, the CAO of CORT sold 5,000.00 shares for a total of $163,650.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics (CORT) Company Description:
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Read More on CORT:
- Corcept Therapeutics management to meet with Piper Sandler
- Truist upgrades Corcept to Buy on three key growth drivers
- Corcept Therapeutics upgraded to Buy from Hold at Truist
- Corcept Therapeutics price target raised to $37 from $35 at Canaccord
- Corcept Therapeutics price target raised to $50 from $47.50 at Ladenburg
